To evaluate the ability of serum VCAM-1, MCP-1 and ADMA levels for discriminating patients with RA-ILD+ from those with RA-ILD-, ROC curves were drawn for each biomarker (Figure 2A). This evidence concerns the gene CCL2 and rheumatoid arthritis.